The effect of galanin gene polymorphism rs948854 on the severity of multiple sclerosis: A significant association with the age of onset.

Background: Data on genetic markers that determine the prognosis of multiple sclerosis (MS) is still limited. The association between galanin gene polymorphism rs948854 and prognosis of MS had been demonstrated earlier.

Objectives: To confirm earlier findings in a distinct from the previously studied cohort of patients, and to further characterized the rs948854 polymorphism as one of the candidates for the risk stratification in patients with MS.

A common genetic variant rs2821557 in KCNA3 is linked to the severity of multiple sclerosis.

The rate of symptom accumulation distinguishes between slowly and rapidly progressing forms of multiple sclerosis (MS). Given that a patient's genetics can affect the rate of disease progression, identification of genetic variants associated with rapid disease progression should provide valuable information for timely prognosis and development of optimal treatment plans. We hypothesized that the polymorphism rs2821557 in the human KCNA3 gene encoding a voltage-gated potassium channel Kv1.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Alemtuzumab (Lemtrada™) is a humanized monoclonal antibody approved in more than 50 countries. Within the European Union, alemtuzumab is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features; in the USA, the indication states that alemtuzumab should generally be reserved for the treatment of patients with relapsing forms of multiple sclerosis who have had an inadequate response to two or more disease-modifying therapies (DMTs). In clinical trials, alemtuzumab demonstrated efficacy in treatment-naïve patients with active RRMS and those relapsing on prior DMTs, with a consistent and manageable safety and tolerability profile.